Brentuximab Vedotin Plus Chemotherapy for Stage III or IV Hodgkin Lymphoma Case

Brentuximab Vedotin Plus Chemotherapy for Stage III or IV Hodgkin Lymphoma Case

Current Status
Not Enrolled
Price
Free
Get Started

Author: Dr. Jia Li (Lily) Liu, Internal Medicine PGY-2, McGill University
Reviewer: Dr. Kelly Davison, MD, PhD, Assistant Professor, Department of Medicine, McGill University

After completion of this self-assessment module, the learner will be able to:
1. Describe the staging system for Hodgkin Lymphoma.
2. Describe favourable versus unfavourable risk Hodgkin Lymphoma.
3. Describe the first-line therapy used to treat Stage III or IV Hodgkin Lymphoma.
4. Describe the adverse effects of Brentuximab VedoGn + AVD.

CHS Scientific Planning Committee

Dr. Pallavi Ganguli – Resident Physician, Hematology
Danyal Ladha – Resident Physician, Hematology
Dr. Joanne Britto – Clinical Fellow, Malignant Hematology (Lymphoproliferative Disorders)
Dr. Yan Xu – Fellow Physician, Hematology/Thrombosis
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician,
Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Conflict of Interest: None